Details of the Drug

General Information of Drug (ID: DMF7EX8)

Drug Name
EGFR antisense DNA
Synonyms Antisense therapy, UPCI; EGFR antisense DNA, University of Pittsburgh
Indication
Disease Entry ICD 11 Status REF
Head and neck cancer 2D42 Phase 1/2 [1]
Drug Type
Antisense drug
Cross-matching ID
TTD ID
D06VFF

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
EGFR messenger RNA (EGFR mRNA) TTG96HZ EGFR_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Head and neck tissue
The Studied Disease Head and neck cancer [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
EGFR messenger RNA (EGFR mRNA) DTT EGFR 5.84E-05 0.32 0.55
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT00903461) Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma. U.S. National Institutes of Health.
2 Antitumor Effects of EGFR Antisense Guanidine-Based Peptide Nucleic Acids in Cancer Models. ACS Chem Biol. 2013 February 15; 8(2): 345-352.